{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T03:54:25Z","timestamp":1792814065558,"version":"4.5.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,11,16]],"date-time":"2025-11-16T00:00:00Z","timestamp":1763251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,16]],"date-time":"2025-11-16T00:00:00Z","timestamp":1763251200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004091","name":"Kumamoto University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004091","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Brain Tumor Pathol"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Functioning gonadotroph pituitary neuroendocrine tumors (Gn-PitNETs) cause ovarian hyperstimulation. We report Gn-PitNETs, including a distant metastasis case responsive to a dopamine agonist (DA), cabergoline. A 10-year-old girl presented with ovarian enlargement and elevated FSH levels (33.7 mIU\/mL). A pituitary tumor was resected and confirmed as a Gn-PitNET. Radiotherapy for residual tumor improved ovarian enlargement. At age 20, ovarian enlargement recurred and cabergoline relieved symptoms and decreased FSH levels. At age 35, ovarian enlargement recurred after discontinuing cabergoline but improved with its reinstatement. Liver biopsy confirmed metastatic Gn-PitNET and DRD2 positivity. A 26-year-old woman presented with ovarian enlargement and elevated FSH levels (31.6 mIU\/mL). A pituitary tumor was resected and confirmed as a Gn-PitNET with negative DRD2. FSH levels normalized, and ovarian size improved. A 48-year-old man presented with bitemporal hemianopia. FSH levels were elevated (251.4 mIU\/mL) without testicular enlargement. The pituitary tumor was resected, improving hemianopia and normalizing FSH levels. Histopathology confirmed a Gn-PitNET with strong FSH staining and DRD2 positivity. In a rare case of metastatic Gn-PitNET, cabergoline was associated with tumor stability and hormone control. Further studies may clarify whether DRD2 expression can help predict DA responsiveness in refractory tumors.<\/jats:p>\n                  <jats:p>(200\/200 words)<\/jats:p>","DOI":"10.1007\/s10014-025-00521-3","type":"journal-article","created":{"date-parts":[[2025,11,16]],"date-time":"2025-11-16T20:33:13Z","timestamp":1763325193000},"page":"123-131","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Histopathological evaluation of dopamine receptor D2 expression in symptomatic gonadotroph pituitary neuroendocrine tumors: a case series including a rare metastatic case responsive to a dopamine agonist"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8952-7009","authenticated-orcid":false,"given":"Ken","family":"Uekawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Shinojima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeo","family":"Anai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kozo","family":"Tashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motoyuki","family":"Igata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Matsumura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rumi","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Ohba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hironori","family":"Tashiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhito","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyo","family":"Mabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigetoshi","family":"Yano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshinori","family":"Hirai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiki","family":"Mikami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akitake","family":"Mukasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,16]]},"reference":[{"key":"521_CR1","first-page":"762","volume":"19","author":"GU Mehta","year":"2017","unstructured":"Mehta GU, Lonser RR (2017) Management of hormone-secreting pituitary adenomas. Neuro Oncol 19:762\u2013773","journal-title":"Neuro Oncol"},{"key":"521_CR2","doi-asserted-by":"publisher","first-page":"4423","DOI":"10.1210\/jc.2014-2362","volume":"99","author":"G Ntali","year":"2014","unstructured":"Ntali G, Capatina C, Grossman A et al (2014) Functioning gonadotroph adenomas. J Clin Endocrinol Metab 99:4423\u20134433","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"521_CR3","first-page":"1071","volume":"58","author":"G Ntali","year":"2022","unstructured":"Ntali G, Capatina C (2022) Updating the landscape for functioning gonadotroph tumors. Med (Kaunas) 58(8):1071","journal-title":"Med (Kaunas)"},{"key":"521_CR4","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/S0015-0282(99)00197-1","volume":"72","author":"H Tashiro","year":"1999","unstructured":"Tashiro H, Katabuchi H, Ohtake H et al (1999) A follicle-stimulating hormone-secreting gonadotroph adenoma with ovarian enlargement in a 10-year-old Girl. Fertil Steril 72:158\u2013160","journal-title":"Fertil Steril"},{"key":"521_CR5","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s007950000004","volume":"33","author":"H Tashiro","year":"2000","unstructured":"Tashiro H, Katabuchi H, Ohtake H et al (2000) An immunohistochemical and ultrastructural study of a follicle-stimulating hormone-secreting gonadotroph adenoma occurring in a 10-year-old Girl. Med Electron Microsc 33:25\u201331","journal-title":"Med Electron Microsc"},{"key":"521_CR6","volume-title":"WHO classification of tumours of the digestive system","author":"FCF Bosman","year":"2010","unstructured":"Bosman FCF, Hruban R, Theise N (2010) WHO classification of tumours of the digestive system. IARC;, Lyon"},{"key":"521_CR7","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.humpath.2017.11.008","volume":"72","author":"A Kasajima","year":"2018","unstructured":"Kasajima A, Papotti M, Ito W et al (2018) High interlaboratory and interobserver agreement of somatostatin receptor immunohistochemical determination and correlation with response to somatostatin analogs. Hum Pathol 72:144\u2013152","journal-title":"Hum Pathol"},{"key":"521_CR8","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s13046-014-0056-y","volume":"33","author":"Y Wang","year":"2014","unstructured":"Wang Y, Li J, Tohti M et al (2014) The expression profile of dopamine D2 receptor, MGMT and VEGF in different histological subtypes of pituitary adenomas: a study of 197 cases and indications for the medical therapy. J Exp Clin Cancer Res 33:56","journal-title":"J Exp Clin Cancer Res"},{"key":"521_CR9","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1111\/cen.12684","volume":"82","author":"L Vieira Neto","year":"2015","unstructured":"Vieira Neto L, Wildemberg LE, Moraes AB et al (2015) Dopamine receptor subtype 2 expression profile in nonfunctioning pituitary adenomas and in vivo response to Cabergoline therapy. Clin Endocrinol 82:739\u2013746","journal-title":"Clin Endocrinol"},{"key":"521_CR10","doi-asserted-by":"crossref","unstructured":"Ahmad Fauzi MF, Wan Ahmad W, Jamaluddin MF et al (2022) Allred scoring of ER-IHC stained Whole-Slide images for hormone receptor status in breast carcinoma. Diagnostics (Basel) 12(12):3093","DOI":"10.3390\/diagnostics12123093"},{"key":"521_CR11","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1111\/his.12662","volume":"67","author":"E Specht","year":"2015","unstructured":"Specht E, Kaemmerer D, Sanger J et al (2015) Comparison of immunoreactive score, HER2\/neu score and H score for the immunohistochemical evaluation of somatostatin receptors in bronchopulmonary neuroendocrine neoplasms. Histopathology 67:368\u2013377","journal-title":"Histopathology"},{"key":"521_CR12","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1038\/modpathol.3800954","volume":"20","author":"M Volante","year":"2007","unstructured":"Volante M, Brizzi MP, Faggiano A et al (2007) Somatostatin receptor type 2A immunohistochemistry in neuroendocrine tumors: a proposal of scoring system correlated with somatostatin receptor scintigraphy. Mod Pathol 20:1172\u20131182","journal-title":"Mod Pathol"},{"key":"521_CR13","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s12022-022-09703-7","volume":"33","author":"SL Asa","year":"2022","unstructured":"Asa SL, Mete O, Perry A et al (2022) Overview of the 2022 WHO classification of pituitary tumors. Endocr Pathol 33:6\u201326","journal-title":"Endocr Pathol"},{"key":"521_CR14","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1007\/s11102-023-01341-4","volume":"26","author":"AG Yearley","year":"2023","unstructured":"Yearley AG, Chalif EJ, Gupta S et al (2023) Metastatic pituitary tumors: an institutional case series. Pituitary 26:561\u2013572","journal-title":"Pituitary"},{"key":"521_CR15","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1507\/endocrj.EJ23-0007","volume":"70","author":"H Nishioka","year":"2023","unstructured":"Nishioka H (2023) Aggressive pituitary tumors (PitNETs). Endocr J 70:241\u2013248","journal-title":"Endocr J"},{"key":"521_CR16","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1507\/endocrj.49.153","volume":"49","author":"K Suzuki","year":"2002","unstructured":"Suzuki K, Morii K, Nakamura J et al (2002) Adrenocorticotropin-producing pituitary carcinoma with metastasis to the liver in a patient with cushing\u2019s disease. Endocr J 49:153\u2013158","journal-title":"Endocr J"},{"key":"521_CR17","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s13000-020-00997-x","volume":"15","author":"ER Venable","year":"2020","unstructured":"Venable ER, Kerr SE, Lopes MBS et al (2020) Liver metastases from pituitary carcinomas mimicking visceral well-differentiated neuroendocrine tumors: a series of four cases. Diagn Pathol 15:81","journal-title":"Diagn Pathol"},{"key":"521_CR18","doi-asserted-by":"publisher","first-page":"1168.e5","DOI":"10.1016\/j.fertnstert.2009.06.023","volume":"92","author":"J Burgos","year":"2009","unstructured":"Burgos J, Cobos P, Vidaurrazaga N et al (2009) Ovarian hyperstimulation secondary to ectopic secretion of follicle-stimulating hormone. Literature review prompted by a case. Fertil Steril 92:1168.e5\u20131168.e8","journal-title":"Fertil Steril"},{"key":"521_CR19","doi-asserted-by":"publisher","first-page":"e162","DOI":"10.1016\/j.wneu.2021.02.115","volume":"150","author":"H Hasegawa","year":"2021","unstructured":"Hasegawa H, Nesvick CL, Erickson D et al (2021) Gonadotroph pituitary adenoma causing treatable infertility and ovarian hyperstimulation syndrome in female patients: Neurosurgical, Endocrinologic, Gynecologic, and reproductive outcomes. World Neurosurg 150:e162\u2013e175","journal-title":"World Neurosurg"},{"key":"521_CR20","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1093\/ejendo\/lvae055","volume":"190","author":"D Zhang","year":"2024","unstructured":"Zhang D, Hugo W, Bergsneider M et al (2024) Cabergoline targets multiple pathways to inhibit PRL secretion and increases stromal fibrosis. Eur J Endocrinol 190:467\u2013478","journal-title":"Eur J Endocrinol"},{"key":"521_CR21","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1007\/s40618-021-01661-x","volume":"45","author":"R Pivonello","year":"2022","unstructured":"Pivonello R, Pivonello C, Simeoli C et al (2022) The dopaminergic control of cushing\u2019s syndrome. J Endocrinol Invest 45:1297\u20131315","journal-title":"J Endocrinol Invest"},{"key":"521_CR22","doi-asserted-by":"publisher","first-page":"102883","DOI":"10.1016\/j.arcmed.2023.102883","volume":"54","author":"I Shimon","year":"2023","unstructured":"Shimon I (2023) Prolactinomas resistant to dopamine agonists: pathophysiology and treatment. Arch Med Res 54:102883","journal-title":"Arch Med Res"},{"key":"521_CR23","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s12020-023-03310-0","volume":"80","author":"H Tang","year":"2023","unstructured":"Tang H, Cheng Y, Lou X et al (2023) DRD2 expression based on (18)F-fallypride PET\/MR predicts the dopamine agonist resistance of prolactinomas: a pilot study. Endocrine 80:419\u2013424","journal-title":"Endocrine"},{"key":"521_CR24","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.humpath.2013.08.007","volume":"45","author":"L Chinezu","year":"2014","unstructured":"Chinezu L, Vasiljevic A, Jouanneau E et al (2014) Expression of somatostatin receptors, SSTR2A and SSTR5, in 108 endocrine pituitary tumors using immunohistochemical detection with new specific monoclonal antibodies. Hum Pathol 45:71\u201377","journal-title":"Hum Pathol"},{"key":"521_CR25","doi-asserted-by":"crossref","unstructured":"Ilie MD, Vasiljevic A, Louvet C et al (2020) Gonadotroph tumors show subtype differences that might have implications for therapy. Cancers (Basel), 12(4):1012","DOI":"10.3390\/cancers12041012"},{"key":"521_CR26","doi-asserted-by":"publisher","first-page":"R121","DOI":"10.1530\/EJE-13-1031","volume":"170","author":"G Raverot","year":"2014","unstructured":"Raverot G, Jouanneau E, Trouillas J (2014) Management of endocrine disease: clinicopathological classification and molecular markers of pituitary tumours for personalized therapeutic strategies. Eur J Endocrinol 170:R121\u2013132","journal-title":"Eur J Endocrinol"}],"container-title":["Brain Tumor Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10014-025-00521-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10014-025-00521-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10014-025-00521-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T10:01:46Z","timestamp":1784196106000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10014-025-00521-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,16]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["521"],"URL":"https:\/\/doi.org\/10.1007\/s10014-025-00521-3","relation":{},"ISSN":["1433-7398","1861-387X"],"issn-type":[{"value":"1433-7398","type":"print"},{"value":"1861-387X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,16]]},"assertion":[{"value":"19 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written, informed consent was obtained from the patients and their family members for pathological analysis and publication under our approved protocol (No. 1760).","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}